C3.ai Stock Rebounds on Potential Interest Rate Cuts in 2024\n\nC3.ai (NYSE:AI) has been on a rollercoaster ride since its IPO in late 2020. After a strong start, the stock has pulled back significantly in recent months, causing concern among investors. Today the stock is bouncing back, up 11.7% as of 11:45 a.m. EST.\n\n No company-specific news, opportunistic investors appear to be taking advantage of the recent dip in the stock market and scooping up shares of C3.ai. This comes as the U.S. Federal Reserve signaled multiple interest-rate reductions in 2024, providing a boost to growth stocks like C3.ai.\n\nThe Federal Reserve’s decision to leave benchmark interest rates unchanged at a targeted range of between 5.25% and 5.5% was met with a rally in the broader market. It was the news of potential rate cuts in 2024 that excited investors in growth stocks. This will be the first time the Fed has reduced rates since March 2022, when they began raising rates to combat high inflation.\n\nWith the potential for lower rates, C3.ai may have an easier time raising funds and maximizing profitability. The company has been implementing cost-cutting measures and is on track to deliver positive cash flow and its first adjusted net profit in the coming years.\n\n The recent dip in its stock price, C3.ai remains an attractive choice for investors seeking growth and resilience in the AI industry. The company’s strong fundamentals and strategic initiatives have yielded impressive results, making it an attractive choice for those looking to invest in the media industry.\n\n C3.ai’s stock saw a significant rebound today, driven by the Federal Reserve’s decision to potentially reduce interest rates in 2024.

Moderna (MRNA) Shares Rise on Positive Trial Results and CDC Alert for Increased Immunization Coverage\n\nModerna (MRNA) shares saw a significant increase of over 9% on Thursday following positive trial results for a collaborative skin cancer treatment with Merck (MRK). This treatment combines a vaccine with the drug Keytruda. In contrast, Pfizer (PFE) disappointed investors this week with its 2024 guidance. Yahoo Finance Health Reporter Anjalee Khemlani provides expert insight and highlights the top stories and biggest drivers behind pharmaceutical stocks on Thursday.\n\nThe U.S. Centers for Disease Control and Prevention (CDC) issued an alert on Thursday urging healthcare providers to increase immunization coverage for influenza, COVID-19, and respiratory syncytial virus (RSV). The CDC expressed concern over low vaccination rates and the potential for increased disease severity and strain on healthcare capacity in the coming weeks. They recommend antiviral medications for influenza and COVID-19 for all eligible patients, particularly older adults and those with underlying medical conditions.\n\nAccording to CDC data, hospitalizations for influenza, COVID-19, and RSV have increased significantly in the past four weeks, with a 200% increase for influenza, 51% for COVID-19, and 60% for RSV. The CDC also reported a decrease of 7.4 million influenza vaccine doses administered to adults compared to the previous season. There has been an increase in RSV and COVID-19 vaccinations among adults aged 60 and above, with 16% and 36% respectively.\n\nPfizer, Moderna, and Novavax have all developed COVID-19 vaccines that are approved in the United States, with Pfizer also having an approved RSV vaccine. This news comes as the Dow Jones index reached another high, although the market weakened in afternoon trading. CAT stock saw a jump in response to this news.\n\n Moderna's positive trial results and Pfizer's disappointing guidance have been the main drivers behind the pharmaceutical market on Thursday.